Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Douglas Scott

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2005
The economic burden of drug resistanceDavid H Howard, R Douglas Scott
Emerging Infectious Diseases|August 25, 2004
Collecting data to assess SARS interventionsR Douglas Scott, Edward Gregg, Martin I Meltzer
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|March 1, 2019
Understanding the Economic Impact of Health Care-Associated Infections: A Cost Perspective AnalysisR Douglas Scott, Steven D Culler, Kimberly J Rask
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2003
The global impact of drug resistanceDavid H Howard, R Douglas Scott, Randall Packard, et al.
Pediatrics|May 4, 2005
Cost-effectiveness of conjugate meningococcal vaccination strategies in the United StatesColin W Shepard, Ismael R Ortega-Sanchez, R Douglas Scott, et al.
American Journal of Preventive Medicine|July 18, 2002
Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysisR Douglas Scott, Martin I Meltzer, Lonny J Erickson, et al.
Infection Control and Hospital Epidemiology|March 19, 2015
The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship programRachel B Slayton, R Douglas Scott, James Baggs, et al.
Emerging Infectious Diseases|October 27, 2004
West Nile virus economic impact, Louisiana, 2002Armineh Zohrabian, Martin I Meltzer, Raoult Ratard, et al.
Antimicrobial Resistance and Infection Control|January 26, 2019
Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent <i>Clostridioides difficile</i> infection in US hospitalsR Douglas Scott, Rachel B Slayton, Fernanda C Lessa, et al.
Health Affairs (Project Hope)|June 4, 2014
CDC central-line bloodstream infection prevention efforts produced net benefits of at least $640 Million during 1990-2008R Douglas Scott, Ronda Sinkowitz-Cochran, Matthew E Wise, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2005
The economic burden of drug resistanceDavid H Howard, R Douglas Scott
Emerging Infectious Diseases|August 25, 2004
Collecting data to assess SARS interventionsR Douglas Scott, Edward Gregg, Martin I Meltzer
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|March 1, 2019
Understanding the Economic Impact of Health Care-Associated Infections: A Cost Perspective AnalysisR Douglas Scott, Steven D Culler, Kimberly J Rask
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2003
The global impact of drug resistanceDavid H Howard, R Douglas Scott, Randall Packard, et al.
Pediatrics|May 4, 2005
Cost-effectiveness of conjugate meningococcal vaccination strategies in the United StatesColin W Shepard, Ismael R Ortega-Sanchez, R Douglas Scott, et al.
American Journal of Preventive Medicine|July 18, 2002
Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysisR Douglas Scott, Martin I Meltzer, Lonny J Erickson, et al.
Infection Control and Hospital Epidemiology|March 19, 2015
The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship programRachel B Slayton, R Douglas Scott, James Baggs, et al.
Emerging Infectious Diseases|October 27, 2004
West Nile virus economic impact, Louisiana, 2002Armineh Zohrabian, Martin I Meltzer, Raoult Ratard, et al.
Antimicrobial Resistance and Infection Control|January 26, 2019
Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent <i>Clostridioides difficile</i> infection in US hospitalsR Douglas Scott, Rachel B Slayton, Fernanda C Lessa, et al.
Health Affairs (Project Hope)|June 4, 2014
CDC central-line bloodstream infection prevention efforts produced net benefits of at least $640 Million during 1990-2008R Douglas Scott, Ronda Sinkowitz-Cochran, Matthew E Wise, et al.
Pageof 2